April 12, 2013

The Food and Drug Administration is granting an expedited application process to a company that has developed a treatment for a condition related to Parkinson's disease, meaning that it can cancel a planned late-stage clinical trial, the company said.

April 12, 2013

Celgene Corp. chairman and CEO Robert Hugin has been elected as chairman of a pharmaceutical industry trade group.

April 12, 2013

Drug companies' pharmaceutical portfolio management teams spend most of their time and budgets supporting niche products, according to a new study.

April 12, 2013

The Food and Drug Administration has approved a contraceptive therapy made by Lupin Pharmaceuticals, the Indian drug maker said Friday.

April 8, 2013

Teva Pharmaceutical Industries has launched a generic opioid medication for treating pain, the company said.

April 5, 2013

Actavis will market and distribute an authorized generic version of a genital herpes ointment made by Valeant Pharmaceuticals International, the companies said Friday.

April 4, 2013

Swiss drug maker Covis Pharma will buy U.S. rights to five drugs from Sanofi, Covis said.

April 4, 2013

The Food and Drug Administration has given preliminary approval to a drug made by Aurobindo Pharma for treating HIV infection, the drug maker said.

April 4, 2013

Novartis is promoting the multiple sclerosis drug Gilenya to young people with a new ad campaign in several national magazine's and websites, according to published reports.

April 2, 2013

A court has ruled in favor of generic drug maker Actavis concerning its generic version of a drug to treat asthma in children, the company said.

April 2, 2013

A ruling by India's high court means cheaper generic versions of a cancer drug will remain available in developing countries, according to published reports.

April 1, 2013

The Food and Drug Administration has approved a new contraceptive therapy made by Teva Pharmaceutical Industries, Teva said Monday.

March 28, 2013

The generic drug industry's main trade group in Washington has hired a prominent lobbyist to head its government affairs team.

March 26, 2013

The Food and Drug Administration has declined to approve a bird flu vaccine made by GlaxoSmithKline due to an administrative issue, the drug maker said.

March 25, 2013

Generic drug maker Actavis has reached a deal with AstraZeneca that will allow it to launch a version of a drug used to treat cholesterol in three years, Actavis said Monday.

March 25, 2013

More than 400 drugs are under development for the 10 most common chronic health conditions affecting elderly people, according to a new report by a drug industry trade group.

March 25, 2013

Boehringer Ingelheim and Eli Lilly are seeking regulatory approval for an experimental drug to treat Type 2 diabetes, the companies said.

March 25, 2013

The Supreme Court heard arguments Monday in a case that could determine the future of generic drugs in America.

March 22, 2013

AstraZeneca will pay $420 million to Moderna Therapeutics in a deal to develop drugs for a variety of diseases using a technology developed by Moderna, AstraZeneca said.

March 22, 2013

Disease relapse rates and worsening of disability were low among patients taking a drug made by Genzyme for multiple sclerosis, the company said.

March 22, 2013

Walgreens and Alliance Boots entered into a 10-year contract with wholesaler AmerisourceBergen on sourcing pharmaceuticals last week. But that's not all. Besides the long-term contract, Walgreens and Alliance Boots will have the option on a potential 23% equity stake in ABC in three years.

The deal takes pharmaceutical buying leverage to the stratosphere and changes the face of more than one health service industry. As Adam Fein, president of Pembroke Consulting, noted in a live television interview on Fox Business' "Money With Melissa Francis": "Three of the largest companies in the pharmaceutical industry have come together and built the single largest buyer of prescription drugs in the world," he said.

March 21, 2013

Gov. Bob McDonnell of Virginia has signed into law the first bill that could limit the reach of follow-on biologics, though the bill includes a two-year sunset clause, meaning it will expire in 2015.

March 20, 2013

Teva Pharmaceutical Industries has appointed a former executive from Dyax to its executive team, the Israeli generic drug maker said.

March 19, 2013

The Food and Drug Administration has picked Kathleen Uhl to serve as acting director of the Office of Generic Drugs, the agency said.